Key Insights

Highlights

Success Rate

83% trial completion

Published Results

88 trials with published results (14%)

Research Maturity

288 completed trials (44% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

9.0%

58 terminated out of 648 trials

Success Rate

83.2%

-3.3% vs benchmark

Late-Stage Pipeline

9%

56 trials in Phase 3/4

Results Transparency

31%

88 of 288 completed with results

Key Signals

88 with results83% success58 terminated

Data Visualizations

Phase Distribution

475Total
Not Applicable (153)
Early P 1 (8)
P 1 (133)
P 2 (125)
P 3 (38)
P 4 (18)

Trial Status

Completed288
Unknown109
Recruiting106
Terminated58
Not Yet Recruiting30
Active Not Recruiting28

Trial Success Rate

83.2%

Benchmark: 86.6%

Based on 288 completed trials

Clinical Trials (648)

Showing 20 of 20 trials
NCT00034216Recruiting

Collection of Blood From Patients With Cancer

NCT04715191Phase 1RecruitingPrimary

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

NCT05600933Enrolling By Invitation

Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment

NCT07010315RecruitingPrimary

Development and Testing of a Patient-facing Educational Tool About Liver Cancer Prevention

NCT07653594Not ApplicableNot Yet Recruiting

TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE)

NCT07059884Not ApplicableRecruiting

Distance-Based Exercise to Preserve Function and Prevent Disability

NCT06091930Phase 1Terminated

A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

NCT03143270Early Phase 1CompletedPrimary

A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer

NCT07741903Not Yet RecruitingPrimary

Development of a Risk Prediction Model for Immune-Targeted Therapy-Related Diarrhea in Patients With Hepatocellular Carcinoma Based on TCM Constitutional Types: A Prospective Cohort Study

NCT03383458Phase 3Active Not Recruiting

A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

NCT02523443Phase 3Active Not RecruitingPrimary

Patient Controlled Epidural Analgesia Versus Intravenous Patient Controlled Analgesia for Post-Operative Pain Control in Patients Undergoing Elective Liver Resection

NCT07124000Recruiting

DESTINY-PANTUMOUR04

NCT07690683Not ApplicableNot Yet Recruiting

Patients With Hepatocellular Carcinoma (HCC)

NCT07717437RecruitingPrimary

DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.

NCT05492136Not ApplicableRecruitingPrimary

Unravelling the Impact of Radiofrecuency in Liver Surgery: the Key to Decrease Local Recurrence?

NCT05128032Not ApplicableCompletedPrimary

Pressure-enabled Delivery in Radioembolization (TriNav Study)

NCT04545957Not ApplicableRecruiting

Jump: MR Simulation For Radiation Therapy Master Protocol

NCT06904365Active Not Recruiting

Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women

NCT06580002Phase 2Recruiting

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

NCT07341737Phase 1Recruiting

SL-28 for Advanced Solid Tumours

Scroll to load more

Research Network

Activity Timeline